Epidemiologic and clinical characteristics of multisystem inflammatory syndrome in adults: a rapid review.
COVID-19
MIS-A
MIS-C
SARS-CoV-2
multisystem inflammatory syndrome in adult
Journal
Canada communicable disease report = Releve des maladies transmissibles au Canada
ISSN: 1188-4169
Titre abrégé: Can Commun Dis Rep
Pays: Canada
ID NLM: 9303729
Informations de publication
Date de publication:
08 Jul 2021
08 Jul 2021
Historique:
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
8
2021
Statut:
epublish
Résumé
Multisystem inflammatory disease in children (MIS-C) is one of the severe presentations of the coronavirus disease 2019 (COVID-19) that has been described in the literature since the beginning of the pandemic. Although MIS-C refers to children, cases with similar clinical characteristics have been recently described in adults. A description of the epidemiologic and clinical characteristics of multisystem inflammatory disease in adults (MIS-A) is a starting point for better knowledge and understanding of this emerging disease. We identified nine case reports of MIS-A in the literature, five from the United States, two from France and two from the United Kingdom. The case descriptions revealed similarities in clinical features, including occurrence during post-acute disease phase, fever, digestive symptoms, cardiac involvement and elevated inflammatory markers. All the patients were hospitalized, three required admission to the intensive care unit and one died. The most common treatments were intravenous immunoglobulin, prednisolone and aspirin. These findings suggest that MIS-A is a severe complication of COVID-19 disease that can lead to death. Further studies to improve our understanding of the pathogenesis of MIS-A, which will help improve treatment decisions and prevent sequelae or death.
Identifiants
pubmed: 34421386
doi: 10.14745/ccdr.v47i78a03
pii: 477803
pmc: PMC8340674
doi:
Types de publication
Journal Article
Langues
eng
Pagination
305-315Déclaration de conflit d'intérêts
Competing interests None.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
BMC Infect Dis. 2020 Sep 29;20(1):716
pubmed: 32993540
Mod Pathol. 2020 Nov;33(11):2128-2138
pubmed: 32572155
Paediatr Respir Rev. 2021 Jun;38:51-57
pubmed: 32891582
MMWR Morb Mortal Wkly Rep. 2020 Oct 09;69(40):1450-1456
pubmed: 33031361
Eur Heart J Cardiovasc Imaging. 2021 Apr 28;22(5):e17
pubmed: 32887992
Am J Med. 2021 Jan;134(1):e36-e37
pubmed: 32712145
BMJ. 2020 May 15;369:m1990
pubmed: 32414749
Am J Emerg Med. 2021 Jan;39:253.e1-253.e2
pubmed: 32631771
Lancet Rheumatol. 2020 Sep;2(9):e520-e521
pubmed: 32838310
Ann Intern Med. 2020 Dec 15;173(12):1025-1027
pubmed: 32726150
Lancet. 2020 Jul 25;396(10246):e8-e10
pubmed: 32659211
J Infect. 2007 Dec;55(6):488-94
pubmed: 17953991
Dermatology. 2015;231(1):5-8
pubmed: 25998570
Front Immunol. 2021 Jun 23;12:680567
pubmed: 34248962
Respir Investig. 2020 Sep;58(5):409-418
pubmed: 32653383
Am J Ophthalmol Case Rep. 2020 Dec;20:100875
pubmed: 32839740
Chest. 2021 Feb;159(2):471-472
pubmed: 33285106